FDA backs uniQure BLA pathway for AMT-130

uniQure's gene therapy candidate AMT-130 has received a significant boost as the FDA has backed its Biologics License Application (BLA) pathway. This decision is expected to positively impact the company's stock, signaling a clearer regulatory route for their treatment. The therapy targets Huntington's disease, and this FDA endorsement represents a crucial step forward in potentially bringing a new therapeutic option to patients. Investors are likely to view this development favorably, anticipating further progress towards clinical trials and eventual market approval.